Finance

Lists
600998:SHA
Jointown Pharmaceutical Group Co Ltd
4,93 CN¥
-1,79%
(-0,090) 1D
16-окт., 15:00:01 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600998...
Open
5,02 CN¥
High
5,08 CN¥
Low
4,88 CN¥
Mkt. cap
24,86 млд
Avg. vol.
33,74 млн
Volume
44,94 млн
Dividend
4,06%
Quarterly dividend
0,05 CN¥
Ex-dividend date
2026-ж., 8-июн.
P/E ratio
12,56
52-wk high
5,84 CN¥
52-wk low
4,48 CN¥
EPS
0,39 CN¥
Shares outstanding
1,88 млд
No. of employees
30 миң
Open
5,02 CN¥
High
5,08 CN¥
Low
4,88 CN¥
Mkt. cap
24,86 млд
Avg. vol.
33,74 млн
Volume
44,94 млн
Dividend
4,06%
Quarterly dividend
0,05 CN¥
Ex-dividend date
2026-ж., 8-июн.
P/E ratio
12,56
52-wk high
5,84 CN¥
52-wk low
4,48 CN¥
EPS
0,39 CN¥
Shares outstanding
1,88 млд
No. of employees
30 миң
News stories
From web sources and news partners
Profile
Jointown Pharmaceutical Group Co., Ltd. is a publicly traded multinational healthcare services company. By revenue, it is the largest medical company in China that is not state-owned. It is also the 4th largest overall. Its global headquarters are in Wuhan, China and its international headquarters are in Los Angeles, California. The company specializes in the distribution of pharmaceuticals and medical products, distributing more than 510,000 products. The company also manufactures products, including gloves, surgical masks, medical equipment and medications. In addition, it operates the largest network of medical warehouses in China. It is one of the largest in the world, at over 44 million square feet. The company has over 400 subsidiaries and provides medical products to all 31 provinces in mainland China. Wikipedia
About Jointown Pharmaceutical Group Co Ltd
CEO-
Employees29,9 миң
Founded2000
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
38,22 млд
42,06 млд
44,78 млд
42,50 млд
Cost of goods sold
35,00 млд
38,94 млд
41,44 млд
39,12 млд
Cost of revenue
35,00 млд
38,94 млд
41,44 млд
39,12 млд
Research and development expenses
31,00 млн
31,05 млн
24,25 млн
35,77 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,07 млд
2,21 млд
2,07 млд
2,24 млд
Operating expense
2,18 млд
2,54 млд
2,37 млд
2,45 млд
Total operating expenses
37,17 млд
41,49 млд
43,81 млд
41,57 млд
Operating income
1,05 млд
577,21 млн
971,28 млн
922,06 млн
Other non operating income
-10,19 млн
-23,03 млн
-15,38 млн
-57,14 млн
EBT including unusual items
706,81 млн
590,98 млн
762,47 млн
810,81 млн
EBT excluding unusual items
868,16 млн
402,66 млн
702,61 млн
619,67 млн
Income tax expense
148,37 млн
258,61 млн
167,28 млн
213,41 млн
Effective tax rate
20,99%
43,76%
21,94%
26,32%
Other operating expenses
7,64 млн
209,56 млн
45,26 млн
169,00 млн
Net income
529,89 млн
279,41 млн
733,16 млн
467,41 млн
Net profit margin
1,39%
0,66%
1,64%
1,10%
Earnings per share
0,10
0,05
0,11
0,08
Interest and investment income
65,37 млн
122,28 млн
65,73 млн
31,49 млн
Interest expense
-245,91 млн
-262,58 млн
-319,03 млн
-279,26 млн
Net interest expenses
-180,54 млн
-140,30 млн
-253,30 млн
-247,77 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,22 млд
728,70 млн
1,12 млд
1,11 млд
Gain or loss from assets sale
-238,51 млн
244,27 млн
-
20,61 млн
AI content may include mistakes. Learn more
Google колдонмолору